Renaissance Technologies’s Bio-Rad Laboratories Class A BIO Stock Holding History

Renaissance Technologies’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,100	Closed	-$417K	–	3675
2023 Q2	$417K	Sell	1,100 -37,100	-97%	-$15.1M	﹤0.01%	2973
2023 Q1	$18.3M	Sell	38,200 -63,943	-63%	-$29.9M	0.02%	768
2022 Q4	$43M	Buy	102,143 +39,443	+63%	+$15.9M	0.06%	389
2022 Q3	$26.2M	Sell	62,700 -91,800	-59%	-$45.8M	0.04%	547
2022 Q2	$76.5M	Sell	154,500 -33,300	-18%	-$17.3M	0.09%	255
2022 Q1	$106M	Buy	187,800 +131,600	+234%	+$79.3M	0.12%	171
2021 Q4	$42.5M	Buy	56,200 +16,600	+42%	+$12.4M	0.05%	381
2021 Q3	$29.5M	Sell	39,600 -7,300	-16%	-$5.47M	0.04%	492
2021 Q2	$30.2M	Sell	46,900 -4,400	-9%	-$2.68M	0.04%	526
2021 Q1	$29.3M	Buy	+51,300	New	+$30.4M	0.04%	568
2020 Q4	–	Sell	-47,400	Closed	-$24.4M	–	3387
2020 Q3	$24.4M	Buy	47,400 +15,600	+49%	+$7.9M	0.02%	642
2020 Q2	$14.4M	Sell	31,800 -29,900	-48%	-$13.2M	0.01%	1007
2020 Q1	$21.6M	Sell	61,700 -16,700	-21%	-$6.14M	0.02%	726
2019 Q4	$29M	Buy	78,400 +25,100	+47%	+$8.85M	0.02%	798
2019 Q3	$17.7M	Sell	53,300 -78,600	-60%	-$25.6M	0.02%	1029
2019 Q2	$41.2M	Sell	131,900 -24,900	-16%	-$7.46M	0.04%	570
2019 Q1	$47.9M	Buy	156,800 +92,500	+144%	+$25M	0.04%	532
2018 Q4	$14.9M	Sell	64,300 -7,900	-11%	-$2.12M	0.02%	1072
2018 Q3	$22.6M	Sell	72,200 -230,800	-76%	-$71.6M	0.02%	864
2018 Q2	$87.4M	Sell	303,000 -40,700	-12%	-$11.2M	0.1%	242
2018 Q1	$86M	Buy	343,700 +38,400	+13%	+$9.78M	0.09%	245
2017 Q4	$72.9M	Buy	305,300 +214,700	+237%	+$52M	0.08%	292
2017 Q3	$20.1M	Buy	90,600 +4,100	+5%	+$923K	0.02%	897
2017 Q2	$19.6M	Sell	86,500 -3,500	-4%	-$763K	0.03%	861
2017 Q1	$17.9M	Buy	90,000 +58,800	+188%	+$11.3M	0.03%	870
2016 Q4	$5.69M	Sell	31,200 -11,800	-27%	-$2.01M	0.01%	1574
2016 Q3	$7.04M	Sell	43,000 -4,100	-9%	-$622K	0.01%	1397
2016 Q2	$6.74M	Sell	47,100 -97,800	-67%	-$13.9M	0.01%	1414
2016 Q1	$19.8M	Buy	144,900 +63,400	+78%	+$8.32M	0.04%	654
2015 Q4	$11.3M	Sell	81,500 -8,020	-9%	-$1.11M	0.02%	909
2015 Q3	$12M	Buy	89,520 +30,020	+50%	+$4.32M	0.03%	823
2015 Q2	$8.96M	Sell	59,500 -57,700	-49%	-$8.25M	0.02%	1039
2015 Q1	$15.8M	Buy	117,200 +35,000	+43%	+$4.34M	0.03%	701
2014 Q4	$9.91M	Buy	82,200 +7,700	+10%	+$886K	0.02%	890
2014 Q3	$8.45M	Buy	74,500 +13,000	+21%	+$1.54M	0.02%	863
2014 Q2	$7.36M	Buy	61,500 +31,730	+107%	+$3.87M	0.02%	1016
2014 Q1	$3.81M	Buy	29,770 +870	+3%	+$112K	0.01%	1407
2013 Q4	$3.57M	Sell	28,900 -42,800	-60%	-$5.22M	0.01%	1402
2013 Q3	$8.43M	Sell	71,700 -31,500	-31%	-$3.72M	0.02%	888
2013 Q2	$11.6M	Buy	+103,200	New	+$12.1M	0.03%	661

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies's BIO Position: Q3 2023 in Review

Renaissance Technologies sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 1,100 shares — an estimated $417K sold.

Renaissance Technologies first reported a position in BIO in Q2 2013 and held it in 40 quarters. The position peaked at $106M in Q1 2022. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

Renaissance Technologies reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
Renaissance Technologies sold 1,100 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $417K.
Renaissance Technologies first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 40 quarters.
Renaissance Technologies's Bio-Rad Laboratories Class A position peaked at $106M in Q1 2022.
467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.